It has been known for many years that immunosuppressed patients have a diathesis to cancer. Thus in retrospect it is no surprise to find that many patients with human immunodeficiency virus (HIV) infection develop opportunistic cancers. Moreover, the parallels between the acquired immunodeficiency syndrome (AIDS)and cancer are striking both in the laboratory and at the bedside. Much of the fundamental work on AIDS is emerging from cancer research laboratories. The research overlaps at the molecular level. The AIDS virus is closely related to the T-cell leukaemia virus, and discovery of both viruses is claimed by Dr Robert Gallo". The similarity in the viruses is at first sight surprising, for IDS and cancer have opposing effects. Whereas vrralleukaemia entails the uncontrolled proliferation of T-cells, AIDS leads to the death of T-cells and crippling of the immune system.
The pathogenic human retroviruses have been called 'molecular pirates'P, Five different types have so far been described. The first to be discovered was HTLV-I. This virus can be carcinogenic in its own right and probably initiates viral oncogenesis by affecting the cellular genes that regulate growth. The virus may be latent for many years or the patient may develop adult T-cell eukaemia. This may be accompanied by malignant infiltration of the skin in some cases, with the clinical picture of mycosis fungoides or Sezary syndrome. The disease may be further complicated with hypercalcaemia. The precise clinicalsyndromes associated with the laboratory variants and sub-strains require further clarification.
In the case of HTLV-III, now called HIV-1 infection, Kaposi's sarcoma (KS) and non-Hodgkin's lymphomas (NHL) are commonplace, involving up to one-third of all patients. The AIDS epidemic is thus being accompanied by a mini-cancer epidemic. These opportunistic cancers probably stem from viral derangement of immune surveillance. Production ?f growth factors in the tissues may also be Involved. At present HIV-1 is not by itself thought to cause malignant transformation.
K~was first described over 100 years ago by Montz Kaposi. The sporadic occurrence of the tumour in older men of Eastern European origin and 83 endemic forms of the tumour in Africa have long been recognized but the cause remains a mystery. In the past 20 years the tumour has appeared increasingly in patients with iatrogenic immunosuppression and even more dramatically in patients with AIDS. An infectious agent has been suggested", Curiously KS is mostly seen in patients with sexually transmitted AIDS and is rarely found in cases transmitted intravenously. Moreover, the pattern is changing as KS appears to 'bum out' in epidemiologically 'mature' areas. Originally over 50% of homosexual patients with AIDS in San Francisco had KS. This has now fallen to 17%, giving an overall figure of around 30%4. Some argue that this blood vessel tumour is not a true sarcoma and may represent hyperplasia of endothelial tissue. But the distinction between neoplasia and hyperplasia is sometimes blurred. On the one hand, KS may disappear spontaneously when iatrogenic immunosuppression is removed. On the other hand, in its endemic form, the disease often ends in death within 10 years. The initial presentation of early KS in HIV patients sometimes has an innocuous appearance. It is, however, frequently detected at this early stage because of heightened awareness of its appearance in high-risk groups. When a biopsy is taken the pathologist should be informed of the clinical suspicion as the histological diagnosis may be difficult.
HIV-associated NHL is seen in about 5% of AIDS cases. These tumours are all of the B-cell phenotypes. Two main histological types are described: first an immunoblastic or large cell type, HIV-ILCL (60%); second a small non-cleaved Burkitt type, HIV-BL (40%). Clinically HIV-ILCL presents in the final phase of HIV infection with profound CD4 cell impairment. This disease resembles the posttransplant lymphoma with extra nodal and isolated central nervous system (CNS) involvement. Both transplant lymphoma and HIV-ILCL have a high rate of Epstein-Barr virus (EBV) genome integration in tumour cells.
Clinically HIV-BL presents in the early stage of HIV infection. HIV-BL resembles African Burkitt's lymphoma with nodal, visceral, marrow and meninges involvement. In both types there is moderate CD4 cell impairment. The EBV genome is less frequently integrated in HIV-BLtumour cells than in African Burkitt's lymphoma, and the molecular rearrangements of both types are different. < In 1988 Spittle" reported 273 cases of Kaposi's sarcoma in the United Kingdom with 23 cases of non-Hodgkin's lymphoma. Since then many more cases have been documented. A smaller number of cases of Hodgkin's disease, cloacogenic rectal carcinoma, head and neck cancer and teratoma have also been noted, but it is not yet known whether these latter cases are directly related to AIDS.
CANCER MANAGEMENT
The clinical course of AIDS, with its silent onset, insidious illness, profound weight loss and terminal cachexia, is similar to advanced malignant disease. The problem of telling the patient is also sadly familiar.
The treatment of the HIV-associated malignancies is secondary to the treatment of AIDS itself. The aim of cancer-related therapy is mostly palliative relief of symptoms. Indications for treatment of KS are pain, dysfunction and cosmetic disfigurement. The tumour is radiosensitive and small doses of radiation are adequate. Single doses of 800 cGy may be given to multiple small crops of lesions. This is often a convenient way of treating patients who have many other problems. Alternatively, when skin lesions are widespread, total and subtotal body electrons have been used successfully. Doses for total cutaneous electron beam irradiation vary from 1500-3000 cGy over 3-6 weeks", Following radiotherapy, patients have been reported free of Kaposi's sarcoma up to 4 years later. Lesions occurring on the extremities are common and do well. Palliation of pain is achieved in many cases together with improvement of functional deficits and cosmetic appearance. The most difficult malignancies to treat are lesions in mucous membranes. Severe reactions may occur in the oral cavity and radiotherapy should be given cautiously in this area. Doses of up to 1500 cGy in 10 treatments have been recommended. The reactions appear to be due to toxicity rather than lack of response. This probably reflects the ever-present fungal and viral infections which exacerbate the condition in the oropharynx. Prophylactic antifungal and antiviral treatments are always used.
Cytotoxic therapy may also be beneficial in KS and chemotherapy has been used extensively for this lesion especially in the United States. Both systemic and intra-lesional chemotherapy have been used. Complex staging systems have been proposed to evaluate the treatment of HIV-associated KS but these systems are mostly of academic interest.
Treatment results of the HIV-associated NHLs are less satisfactory. Irradiation alone is commonly used to treat NHL involving the CNS. The rate of complete remission is 70%. The mean survival, however, is less than six months, the majority of deaths being due to opportunistic infections. Cyto-toxic chemotherapy is frequently used to treat Widespread HIV-NHL8. Cyclophosphamide, adriamycin, vincristine and prednisolone (CHOP), sometimes in combination with bleomycin, have been recommended'', This chemotherapeutic regimen is occasionally combined with radiotherapy in localized lymphoma. The prognosis in HIV-NHL is related to the status of the underlying infection. In patients with early HIV infection, the two-year survival is 30%; in patients with advanced infection the survival at two years is zero.
As the majority of patients are on other forms of therapy, careful monitoring of the patient's condition is essential, particularly in regard to haematological toxicity and drug interaction. Pneumocystis carinii prophylaxis is, however, essential during cytotoxic cancer therapy. Care must also be taken in prescribing steroids for patients with AIDS. The use of steroids to treat NHL in some patients has been found to increase the risk of developing KS and accelerating its growth.
Terminal care of young patients has always been difficult. Dr Robert Wachter? in California states that not in recent memory have so many relatively young previously healthy people died so quickly, with doctors seemingly powerless to influence the eventual outcome. For junior doctors already burdened with the traditional stresses of residency, involvement in this tragic scenario extracts a substantial psychological toll. If the position of doctors is difficult, the tragic despair of the victims is infinitely worse. Cheated of the future, their sense of exile and deprivation is reminiscent of medieval medicine. An added irony is that many AIDS patients are now pretending they have cancer in order not to die in ignominy and disgrace. The demand for hospice-type care is increasing. Hospices, however, depend crucially on charitable financial support which may not be so readily forthcoming for these new terminal victims. A new network of voluntary support is growing for AIDS, especially from within the homosexual or gay community, and as a consequence strong pressure groups are being established. The AIDS charities are unlikely, however, to be as financially successful as the cancer charities.
OTHER CANCER FEATURES
Some of the difficulties encountered in AIDS education have been found with public cancer education. The human retroviruses are mostly transmitted sexually or intravenously. A worldwide educational campaign against AIDS has been mounted. The saturation coverage that has been achieved has meant that most adults in the western world are aware of the disease. What is less certain is whether this increase in knowledge has led to a change in behaviour. Everyone knows about the association between smoking and lung cancer, yet the smoking habit persists. Sexual practices are more difficult to change. For many young people the risks of smoking lie in the distant future and for many who have not yet witnessed the ravages of AIDS, the risks may seem equally remote. A further danger with AIDS educational programmes is that they sometimes rely on victim blaming. People are exhorted to 'behave themselves'. Unfortunately, blaming the victim sometimes drives the problem underground.
As with the incurable cancers, it is understandable that extravagant claims will continue to be made about effective treatments for AIDS. Terminal victims and their relatives will often do anything and pay anything in the hope of a cure. Rock Hudson's trip to Paris a few years ago was reminiscent of Yul Brynner's futile visit to Germany in search of a cancer cure the previous year, or Steve McQueen's search in Mexico for the apricot derivative Laetrile. Claims for breakthroughs in AIDS are inevitable. Compound Q, a clandestine drug derived from a cucumber plant in China, is a recent example. As with cancer nostrums, bogus claims should be handled sensitively but firmly.
Finally the need for laboratory research to continue is self-evident. Although target-oriented research is essential, it is more likely that significant discoveries and advances will come from fundaental research programmes. As already noted, all biOlogical research, including cancer research and AIDS research, overlaps at the fundamental level.
Lowry. HIV and opportunistic cancers 85
A vaccine for AIDS may prove as elusive as a vaccine for cancer. In this connection the current economic damage to the framework of academic medicine is worrying. Financial support for basic research must be given as an Act of Faith. It is not derived from a Law of Economics.
